IQV vs. ICLR, MEDP, INCY, CRL, TAK, CNC, IDXX, ALC, HUM, and COR
Should you be buying IQVIA stock or one of its competitors? The main competitors of IQVIA include ICON Public (ICLR), Medpace (MEDP), Incyte (INCY), Charles River Laboratories International (CRL), Takeda Pharmaceutical (TAK), Centene (CNC), IDEXX Laboratories (IDXX), Alcon (ALC), Humana (HUM), and Cencora (COR). These companies are all part of the "medical" sector.
ICON Public (NASDAQ:ICLR) and IQVIA (NYSE:IQV) are both large-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, institutional ownership, risk, community ranking and media sentiment.
IQVIA received 40 more outperform votes than ICON Public when rated by MarketBeat users. Likewise, 68.03% of users gave IQVIA an outperform vote while only 64.99% of users gave ICON Public an outperform vote.
In the previous week, IQVIA had 9 more articles in the media than ICON Public. MarketBeat recorded 11 mentions for IQVIA and 2 mentions for ICON Public. IQVIA's average media sentiment score of 0.89 beat ICON Public's score of 0.82 indicating that ICON Public is being referred to more favorably in the media.
ICON Public presently has a consensus price target of $339.44, indicating a potential upside of 7.48%. IQVIA has a consensus price target of $257.57, indicating a potential upside of 9.60%. Given ICON Public's higher possible upside, analysts plainly believe IQVIA is more favorable than ICON Public.
ICON Public has a beta of 1.18, suggesting that its share price is 18% more volatile than the S&P 500. Comparatively, IQVIA has a beta of 1.52, suggesting that its share price is 52% more volatile than the S&P 500.
IQVIA has higher revenue and earnings than ICON Public. IQVIA is trading at a lower price-to-earnings ratio than ICON Public, indicating that it is currently the more affordable of the two stocks.
95.6% of ICON Public shares are owned by institutional investors. Comparatively, 89.6% of IQVIA shares are owned by institutional investors. 44.0% of ICON Public shares are owned by company insiders. Comparatively, 1.6% of IQVIA shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
IQVIA has a net margin of 9.01% compared to IQVIA's net margin of 8.30%. ICON Public's return on equity of 29.17% beat IQVIA's return on equity.
Summary
IQVIA beats ICON Public on 11 of the 18 factors compared between the two stocks.
Get IQVIA News Delivered to You Automatically
Sign up to receive the latest news and ratings for IQV and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IQV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
